19.11.2020 | ASO Author Reflections
ASO Author Reflections: Personalized Surgery in Recurrent Ovarian Cancer Patients
verfasst von:
Felipe Leonardo Estati, Glauco Baiocchi, Alexandre André Balieiro Anastácio da Costa
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 7/2021
Einloggen, um Zugang zu erhalten
Excerpt
Among recurrent ovarian cancer patients, secondary cytoreduction surgery (SCS) improves overall survival (OS), with patient selection playing a central role in the success of SCS.
BRCA1/2 status is an important determinant of disease behavior, and patients who present
BRCA1/2-mutated tumors present a higher sensitivity to chemotherapy and poly(ADP ribose) polymerase (PARP) inhibitors and longer progression-free survival (PFS) and OS after treatment or recurrent disease.
1 Data on the impact of
BRCA1/2 mutations on the benefit of SCS is scarce, with only two studies, with contradictory results, addressing this issue.
2,3 …